Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC

2024-08-27T09:55:48+02:00August 2, 2024|Investor Information, Press Releases, Psychedelic News|

Psyence Biomed today announced the export of nature-derived psilocybin to Australia and provided an update on its upcoming Phase IIb clinical trial evaluating nature‑derived psilocybin as a potential treatment for Adjustment Disorder following an advanced cancer diagnosis in the Palliative Care context.